Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Target Recruit Count
- 30
- Registration Number
- NCT05524155
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 446
- Registration Number
- NCT05462613
- Locations
- 🇫🇷
Hôpital Privé Jean Mermoz, Lyon, France
🇫🇷CHU Estain, Clermont-Ferrand, France
🇫🇷CHU Montpellier, Montpellier, France
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 50
- Registration Number
- NCT05426811
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 874
- Registration Number
- NCT05425940
- Locations
- 🇺🇸
Exelixis Clinical Site #77, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #106, Philadelphia, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #103, Pittsburgh, Pennsylvania, United States
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 30
- Registration Number
- NCT05394740
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Regorafenib in Patients With Refractory Primary Bone Tumors
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Institute of Mother and Child, Warsaw, Poland
- Target Recruit Count
- 30
- Registration Number
- NCT05395741
- Locations
- 🇵🇱
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
🇵🇱the Institute of Mother and Child, Warsaw, Poland
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 48
- Registration Number
- NCT05366816
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 700
- Registration Number
- NCT05328908
- Locations
- 🇧🇪
Local Institution - 0120, Leuven, Belgium
🇨🇭Local Institution - 0057, Aarau, AG, Switzerland
🇧🇪Local Institution - 0070, Edegem, Belgium
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- The Central Hospital of Lishui City
- Target Recruit Count
- 176
- Registration Number
- NCT05233358
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT05198934
- Locations
- 🇯🇵
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
🇺🇸Kelsey Research Foundation, Houston, Texas, United States
🇺🇸Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.